These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7039044)

  • 21. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
    Wolmark N; Fisher B
    Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
    [No Abstract]   [Full Text] [Related]  

  • 22. [Immunotherapy of lung cancer].
    Jassem J; Jassem E
    Pol Tyg Lek; 1982 Jun; 37(17):497-9. PubMed ID: 6292882
    [No Abstract]   [Full Text] [Related]  

  • 23. Possible immunosuppressive effect of Corynebacterium parvum on infection with Trichinella spiralis.
    Ruitenberg EJ; Steerenberg PA
    Nat New Biol; 1973 Apr; 242(118):149-50. PubMed ID: 4512655
    [No Abstract]   [Full Text] [Related]  

  • 24. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum.
    MacEwen EG; Patnaik AK; Harvey HJ; Hayes AA; Matus R
    Cancer Invest; 1986; 4(5):397-402. PubMed ID: 3801954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved survival after pneumococcus in splenectomized and nonsplenectomized mice with Corynebacterium parvum.
    Hebert JC; Gamelli RL; Foster RS; Chalmer BJ; Davis JH
    Arch Surg; 1983 Mar; 118(3):328-32. PubMed ID: 6824432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pleural effusion. Local treatment by Corynebacterium parvum].
    Serrou B; Cupissol D
    Nouv Presse Med; 1980 Jun; 9(25):1777-8. PubMed ID: 7383874
    [No Abstract]   [Full Text] [Related]  

  • 27. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum.
    Hamilton DN; Bell PR
    Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648
    [No Abstract]   [Full Text] [Related]  

  • 28. Experimental nonspecific immunostimulation by the Propionibacterium acnes vaccine.
    Koukalová D; Kod'ousek R; Hájek V; Kolár M
    Acta Univ Palacki Olomuc Fac Med; 1992; 133():19-23. PubMed ID: 1344592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infectious complications in renal transplant recipients: a 10-year review of cyclosporine-based immunosuppression.
    Tsai MK; Lee PH; Hu RH; Lee CJ
    Transplant Proc; 1998 Nov; 30(7):3125-6. PubMed ID: 9838381
    [No Abstract]   [Full Text] [Related]  

  • 30. Studies with a spontaneous mouse tumor. I. Growth in normal mice and response to Corynebacterium parvum.
    Woodruff MF; Whitehead VL; Speedy G
    Br J Cancer; 1978 Mar; 37(3):345-55. PubMed ID: 638014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of cancer using Corynebacterium parvum: similarity of two preparations in four animal tumor models.
    Bartlett GL; Kreider JW; Purnell DM
    Cancer; 1980 Aug; 46(4):685-91. PubMed ID: 7397633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung cancer patients treated with Corynebacterium parvum. Phase I toxicity study.
    Yadeau R; Bates HA; Fortuny I
    Minn Med; 1979 Sep; 62(9):673-5. PubMed ID: 503003
    [No Abstract]   [Full Text] [Related]  

  • 33. Surgery plus Corynebacterium parvum immunotherapy for Lewis lung carcinoma in mice.
    Karrer K; Rella W; Goldin A
    Eur J Cancer (1965); 1979 Jun; 15(6):867-73. PubMed ID: 499275
    [No Abstract]   [Full Text] [Related]  

  • 34. Corynebacterium parvum-induced resistance to a methylcholanthrene fibrosarcoma.
    Gupta JD; Morahan PS; Kaplan AM
    J Reticuloendothel Soc; 1978 Jan; 23(1):1-9. PubMed ID: 627989
    [No Abstract]   [Full Text] [Related]  

  • 35. Abrogation of antitumor effects of Corynebacterium parvum and BCG by antimacrophage agents: brief communication.
    Keller R
    J Natl Cancer Inst; 1977 Dec; 59(6):1751-3. PubMed ID: 200763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of mononuclear phagocytes in decreased hepatic drug metabolism following administration of Corynebacterium parvum.
    Soyka LF; Stephens CC; MacPherson BR; Foster RS
    Int J Immunopharmacol; 1979; 1(2):101-12. PubMed ID: 551956
    [No Abstract]   [Full Text] [Related]  

  • 37. Mitogenicity of Corynebacterium parvum for mouse lymphocytes.
    Zola H
    Clin Exp Immunol; 1975 Dec; 22(3):514-21. PubMed ID: 817854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the effectiveness and adverse effects of a Corynebacterium parvum vaccine made in Czechoslovakia with Coparvax, a British preparation made by Wellcome, in the treatment of malignant pleural effusions].
    Marel M; Melínová L; Bednár M
    Cas Lek Cesk; 1989 Aug; 128(34):1071-4. PubMed ID: 2790915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of corynebacterium parvum in patients with solid tumors.
    Band PR; Jao-King C; Urtasun RC; Haraphongse M
    Cancer Chemother Rep; 1975; 59(6):1139-45. PubMed ID: 769953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The so-called adjuvant Corynebacterium parvum].
    Günther O
    Dtsch Med Wochenschr; 1978 Jan; 103(2):84-5. PubMed ID: 304802
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.